Novartis’ long-awaited separation from its eye care division Alcon completed on schedule today, allowing it to focus its energies on medicinal products. Alcon’s shares made their debut on the ...

From Mar 20, 2002 until its 2011-merger into Novartis, Alcon was publicly listed and traded on the NYSE. In 2011, Novartis completed the acquisition of 100% stake in Alcon. ALC is a #3 (Hold ...

Novartis and eyecare spinout Alcon have agreed to settle bribery charges brought by the US federal authorities, focused on activities in Greece and other countries, for $347 million.

From Mar 20, 2002 until its 2011-merger into Novartis, Alcon was publicly listed and traded on the NYSE. In 2011, Novartis completed the acquisition of 100% stake in Alcon. ALC is a #3 (Hold ...

Novartis Greece and Alcon Pte, a former subsidiary of Novartis AG and current subsidiary of Alcon Inc., agreed to pay $233 million in criminal penalties to resolve the Department of Justice (DOJ ...

The eye-care company Alcon Research has entered into licensing ... such as ranibizumab (Lucentis; Genentech/Novartis), which inhibit the growth of abnormal new blood vessels and bleeding in ...

The spinoff is in line with Novartis' strategy to focus on human prescription drugs, which has been playing out over the past several years with the divestitures of the eye care (Alcon), vaccine ...

Alcon, a division of Novartis, believes that the many benefits of the NGENUITY 3D Visualization System over traditional ocular devices—for example, increased depth of focus and working distance ...

UBS Group, Zurich Insurance Group, Holcim, Swiss Re, Alcon, Novartis and Julius Baer closed higher by 0.3 to 0.85%. Shares of dermatology company Galderma climbed about 1.7%, lifted by an ...

Minister Lokesh seeks Indian Ambassador's cooperation to set up pharma companies in Andhra Pradesh, highlighting investment opportunities.